

# STATE OF COLORADO

---

John W. Hickenlooper, Governor  
Larry Wolk, MD, MSPH  
Executive Director and Chief Medical Officer

Dedicated to protecting and improving the health and environment of the people of Colorado

4300 Cherry Creek Dr. S.  
Denver, Colorado 80246-1530  
Phone (303) 692-2000  
Located in Glendale, Colorado  
[www.colorado.gov/cdphe](http://www.colorado.gov/cdphe)



Colorado Department  
of Public Health  
and Environment

To: Vaccines for Children (VFC) Providers

From: Colorado Immunization Section

Date: January 3, 2014

Re: Limited Availability of MenHiberix® (Hib-MenCY)

---

The Colorado Vaccines for Children (VFC) Program will have a very limited amount of MenHiberix® (Hib-MenCY-TT) available for order starting January 6<sup>th</sup>, 2014. MenHiberix® will be available for order in single doses and can only be ordered for VFC eligible children who are at increased risk for meningococcal disease as explained below.

## Clinical Guidance

This combination vaccine is for use among infants at increased risk for meningococcal disease such as those with: persistent complement pathway deficiencies, infants who have anatomic or functional asplenia (including sickle cell disease), or who are in communities with serogroup C and meningococcal disease outbreaks. Hib-MenCY-TT is not recommended for use in children who are traveling internationally to *N.* meningitis endemic areas.

Hib-MenCY-TT is licensed for use in high-risk infants and toddlers ages 6 weeks through 23 months of age.

CDC recommendations include use in high risk infants aged 2-18 months for prevention of meningitis infection caused by *Neisseria meningitidis* serogroups C and Y and *Haemophilus influenzae* type b. The vaccine series may be initiated as early as 6 weeks of age and the last doses may be administered as late as 23 months of age.

*Primary Series:* 4-dose series of .5 mL IM with doses at 2, 4, 6, and 12-15 months.

*Booster:* MCV4 [Menactra® or Menveo®] should be used as booster doses for children who are given Hib-MenCT-TT as the primary series, and who remain at increased risk for meningococcal disease.

## Ordering Guidance

Menhiberix will be available for order in single doses. The Colorado VFC Program has a very limited supply and you should only order doses if your practice serves infants at increased risk for meningococcal disease that are VFC eligible.

To order MenHiberix® please go here: <http://fs9.formsite.com/ColoradoIMMprogram/MenHiberix/index.html>

When you order, you will be asked to document the increased risk status and the age(s) of any eligible patient(s).

### **Storage Guidance**

#### Before reconstitution

- Lyophilized vaccine vials: Store refrigerated between 2-8°C (36-46°F); *protect from light*
- Diluent: Store refrigerated or at controlled room temperature between 2-25°C (36-77°F); *do not freeze* (discard diluent if it has been frozen)

#### After reconstitution

- Administer immediately following reconstitution
- Do not freeze
- Discard if the vaccine has been frozen